Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways

British Journal of Cancer

Volumn 96, Issue 6, 2007, Pages 918-927

  Hu, X F ^a   Li, J ^a   Yang, E ^a   Vandervalk, S ^a   Xing, P X ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Cripto Mab; MDR; P glycoprotein; Signalling transduction pathways

Indexed keywords

CASPASE 9; CRIPTO ONCOPROTEIN; CYTARABINE; DAUNORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C13; MONOCLONAL ANTIBODY C4; NUCLEOSIDE DERIVATIVE; ONCOPROTEIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; MITOCHONDRION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SCID MOUSE; TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CASPASE 9; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTARABINE; DAUNORUBICIN; DRUG SYNERGISM; ENZYME ACTIVATION; EPIRUBICIN; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; MAP KINASE KINASE 4; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENE PROTEIN V-AKT; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33947365971     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603641     Document Type: Article

References (52)

1. Abd El-Ghaffar HA, Aladle DA, Farahat SE, Abd El-Hady N (2006) P-glycoprotein (P-170) expression in acute leukemias. Hematology 11: 35-41
2. Abdul-Ghani R, Serra V, Gyorffy B, Jurchott K, Solf A, Dietel M, Schafer R (2006) The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25: 1743-1752
3. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M (2003) Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 112: 575-587
4. Bianco C, Strizzi L, Rehman A, Normanno N, Wechselberger C, Sun Y, Khan N, Hirota M, Adkins H, Williams K, Margolis RU, Sanicola M, Salomon DS (2003) A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 63: 1192- 1197
5. Biscardi M, Teodori E, Caporale R, Budriesi R, Balestri F, Scappini B, Gavazzi S, Grossi A (2006) Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk Res 30: 1-8
6. Ciccodicola A, Dono R, Obici S, Simeone A, Zollo M, Persico MG (1989) Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells. EMBO J 8: 1987-1991
7. Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717
8. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241
9. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252
10. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12: 177-186
11. Downward J (1999) How BAD phosphorylation is good for survival. Nat Cell Biol 1: E33-E35
12. Ebert AD, Wechselberger C, Frank S, Wallace-Jones B, Seno M, Martinez-Lacaci I, Bianco C, De Santis M, Weitzel HK, Salomon DS (1999) Cripto-1 induces phosphatidylinositol 3′-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res 59: 4502-4505
13. Fernandez-Calotti P, Jordheim LP, Giordano M, Dumontet C, Galmarini CM (2005) Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma 46: 335-346
14. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542
15. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE (1965) Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18: 522-529
16. Ghetie MA, Ghetie V, Vitetta ES (1999) Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin Cancer Res 5: 3920-3927
17. Ghetie MA, Marches R, Kufert S, Vitetta ES (2004) An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood 104: 178-183
18. Grandage VL, Gale RE, Linch DC, Khwaja A (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19: 586-594
19. Hayes JD, Wolf CR (1990) Molecular mechanisms of drug resistance. Biochem J 272: 281-295
20. Hu XF, Xing PX (2005) Cripto as a target for cancer immunotherapy. Expert Opin Ther Targets 9: 383-394
21. Hu XF, Martin TJ, Bell DR, de Luise M, Zalcberg JR (1990) Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953-2957
22. Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, Lee G, Parkin JD, Zalcberg JR (1999a) Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93: 4086-4095
23. Hu XF, Slater A, Rischin D, Kantharidis P, Parkin JD, Zalcberg J (1999b) Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer 79: 831-837
24. Hu XF, Slater A, Wall DM, Kantharidis P, Parkin JD, Cowman A, Zalcberg JR (1995) Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71: 931-936
25. Hu XF, Slater A, Wall DM, Parkin JD, Kantharidis P, Zalcberg JR (1996) Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res 2: 713-720
26. Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93: 1075-1085
27. Kannan S, De Santis M, Lohmeyer M, Riese II DJ, Smith GH, Hynes N, Seno M, Brandt R, Bianco C, Persico G, Kenney N, Normanno N, Martinez-Lacaci I, Ciardiello F, Stern DF, Gullick WJ, Salomon DS (1997) Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 272: 3330-3335
28. Lee Jr JT, Steelman LS, McCubrey JA (2004) Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64: 8397-8404
29. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L (2006) Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928
30. Minn AJ, Rudin CM, Boise LH, Thompson CB (1995) Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910
31. Morkel M, Huelsken J, Wakamiya M, Ding J, van de Wetering M, Clevers H, Taketo MM, Behringer RR, Shen MM, Birchmeier W (2003) Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 130: 6283-6294
32. Neo SY, Zhang Y, Yaw LP, Li P, Lin SC (2000) Axin-induced apoptosis depends on the extent of its JNK activation and its ability to down-regulate beta-catenin levels. Biochem Biophys Res Commun 272: 144-150
33. Normanno N, De Luca A, Bianco C, Maiello MR, Carriero MV, Rehman A, Wechselberger C, Arra C, Strizzi L, Sanicola M, Salomon DS (2004) Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol 198: 31-39
34. Petros AM, Olejniczak ET, Fesik SW (2004) Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83-94
35. Plo I, Bettaieb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A, Kowalski-Chauvel A, Laurent G, Lautier D (1999) The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett 452: 150-154
36. Saloman DS, Bianco C, Ebert AD, Khan NI, De Santis M, Normanno N, Wechselberger C, Seno M, Williams K, Sanicola M, Foley S, Gullick WJ, Persico G (2000) The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer 7: 199-226
37. Seidensticker MJ, Behrens J (2000) Biochemical interactions in the wnt pathway. Biochim Biophys Acta 1495: 168-182
38. Slinker BK (1998) The statistics of synergism. J Mol Cell Cardiol 30: 723-731
39. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95: 7024-7029
40. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234
41. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ (2000) Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-874
42. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51
43. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE (2001) cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 299: 434-441
44. West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248
45. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331
46. Xing PX, Hu XF, Pietersz GA, Hosick HL, McKenzie IF (2004) Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res 64: 4018-4023
47. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S (2000) Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 60: 4761-4766
48. Yamada Y, Yoshimi N, Sugie S, Suzui M, Matsunaga K, Kawabata K, Hara A, Mori H (1999) Beta-catenin (Ctnnb1) gene mutations in diethylnitrosamine (DEN)-induced liver tumors in male F344 rats. Jpn J Cancer Res 90: 824-828
49. Yamamoto K, Ichijo H, Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-8478
50. Zalcberg JR, Hu XF, Wall DM, Mirski S, Cole S, Nadalin G, De Luise M, Parkin JD, Vrazas V, Campbell L, Kantharidis P (1994) Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer 57: 522-528
51. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628
52. Zhang Y, Qiu WJ, Liu DX, Neo SY, He X, Lin SC (2001) Differential molecular assemblies underlie the dual function of Axin in modulating the WNT and JNK pathways. J Biol Chem 276: 32152-32159